Its Over

Originally posted by 1ronnie: ↑

This was back in 2021:

A law firm in Australia is preparing a fresh class action claim against Mesoblast that alleges misleading or deceptive conduct to investors and breaches of continous disclosure in the way in which the biotech promoted the prospects of its main product candidate, Remestemcel-L.
Specialist class action firm Phi Finney McDonald is preparing a class action against the $1.5 billion company led by founder and chief executive Silviu Itescu on behalf of investors who acquired shares between February 22, 2018 and December 17, 2020.

Silviu Itescu is chief executive and founder of Mesoblast, which is facing several class action lawsuits. Luis Ascui
Mesoblast is already facing multiple class action lawsuits in the US after being accused overseas of making false or misleading statements to investors, as well as failing to disclose material adverse facts about Remestemcel-L.

...looks like people have short memories.

and this release was what that sparked the frenzy all over again

UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) NOTIFIES MESOBLAST THAT AVAILABLE CLINICAL DATA FROM PHASE 3 TRIAL APPEARSUFFICIENT TO SUPPORT BLA SUBMISSION FOR REMESTEMCEL-L IN CHILDREN WITH STEROIDREFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-a

Why is that word 'APPEAR' there and what is it meant to suggest?

Appear Sufficient is not the same as Deemed Sufficient.

Why do you still trust management with a dark history of alleged deceptive conduct?

I never want to discuss MSB here, I have had posted on this stock long ago, you can ask all the guys at the NewBeginning thread who had been involved with the stock back then.

Expand

Nothing at all came of that 1ronnie. Nothing!

The insurance settled for it to go away for a tiny sum. Had the evidence have come out in a court case you would have found that it was not in fact MSB that did any misleading. The FDA moved the goal posts. It would have come out that they were the misleading party IF ANY. What they wanted to see shifted to potency assays which was not an issue prior to that. The FDA's excuse would be that they were learning as they went as they were playing catch up to MSB. They still are.

Anyway, the fact is MSB is UP >300% why you parrot on about blue chps being down various %'s.... in a similar time period.

I suggest to you that you have a blind spot. Can't let go of the past and form a fresh view on new information - a common thing.

Happy not to discuss it again.

They are the regulator and this is not a final judgement which means that APPEAR is the best word you are going to get at this stage. I repeat NOTHING is left in question now - efficacy ticked and now potency assay ticked as to both MOA and composition of the cells and ratios.